Evolus Inc. (EVL)

Market Closed

17 Jul, 06:12

XMUN

€

5. 03

-0.32

-6.0142%

- Market Cap

- P/E Ratio

- Div Yield

0 Volume

-0.57 Eps

€ 5.35

Previous Close

Add Transaction

Day Range

5.03 5.03

Year Range

3.52 8.2

Want to track EVL and more in your Portfolio? 🎯

Get Started For Free

Summary

EVL closed Friday lower at €5.03, a decrease of -6.0142% from Thursday's close, completing a monthly decrease of -18.6024% or -€1.15. Over the past 12 months, EVL stock lost -11.7193%.

EVL is not paying dividends to its shareholders.

The last earnings report, released on May 05, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.0553%, based on the last three reports.

The stock of the company had never split.

The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

EVL Chart

Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 months ago

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.

Zacks | 2 months ago

Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript

Seekingalpha | 4 months ago

Evolus Inc. (EVL) FAQ

What is the stock price today?

The current price is €5.03.

On which exchange is it traded?

Evolus Inc. is listed on XMUN.

What is its stock symbol?

The ticker symbol is EVL.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Evolus Inc. ever had a stock split?

No, there has never been a stock split.

Evolus Inc. Profile

Specialty Retail Industry	Consumer Discretionary Sector	David Moatazedi CEO	XMUN Exchange	US30052C1071 ISIN
US Country	372 Employees	- Last Dividend	- Last Split	8 Feb 2018 IPO Date

Overview

Evolus, Inc. operates within the performance beauty sector, focusing on the cash-pay aesthetic market across the United States, Canada, and Europe. Since its incorporation in 2012, the company has dedicated itself to offering innovative aesthetic products. With its headquarters in Newport Beach, California, Evolus has carved out a niche in the competitive beauty industry by providing alternatives for temporary improvement in the appearance of facial lines and wrinkles.

Products and Services

Jeuveau: This proprietary formulation of 900 kilodalton purified botulinum toxin type A is specifically designed for the temporary improvement of moderate to severe glabellar lines in adults, catering to the demand for non-surgical cosmetic procedures.
Dermal Filler Products:
- Estyme: A dermal filler product offered by Evolus, aiming to address various aesthetic concerns by smoothing out wrinkles and adding volume to facial structures.
- Evolysse: Another dermal filler in Evolus' portfolio, designed to offer patients aesthetic enhancements and corrections with a focus on natural-looking results.

Contact Information

Address: 520 Newport Center Drive

Phone: 949 284 4555

Website: https://www.evolus.com

Blog Affiliate Program About Terms Privacy Help Contact Us